Doris M. Murray

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

David W. Rusnak, Karen Lackey, Karen Affleck et al. · PubMed · 2001 · 738 citations

Medicine, Oncology, Pharmacology +17

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

David W. Rusnak, Karen Affleck, Stuart Cockerill et al. · PubMed · 2001 · 297 citations

Medicine, Oncology, Pharmacology +15

Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line.

Q T Trinh, Elizabeth A. Austin, Doris M. Murray et al. · PubMed · 1995 · 173 citations

Medicine, Oncology, Pharmaceutical Biotechnology +10

Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors

Stephen T. Davis, Bill Benson, H. Neal Bramson et al. · Science · 2001 · 167 citations

Medicine, Oncology, Pharmacology +15

Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines

Micheal D. Gaul, Yu Guo, Karen Affleck et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 59 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12